GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corbus Pharmaceuticals Holdings Inc (LTS:0SZI) » Definitions » Shiller PE Ratio

Corbus Pharmaceuticals Holdings (LTS:0SZI) Shiller PE Ratio : (As of May. 17, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Corbus Pharmaceuticals Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Corbus Pharmaceuticals Holdings Shiller PE Ratio Historical Data

The historical data trend for Corbus Pharmaceuticals Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corbus Pharmaceuticals Holdings Shiller PE Ratio Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Corbus Pharmaceuticals Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Corbus Pharmaceuticals Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corbus Pharmaceuticals Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Corbus Pharmaceuticals Holdings's Shiller PE Ratio falls into.



Corbus Pharmaceuticals Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Corbus Pharmaceuticals Holdings's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Corbus Pharmaceuticals Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.83/131.7762*131.7762
=-0.830

Current CPI (Mar. 2024) = 131.7762.

Corbus Pharmaceuticals Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.587 100.560 -0.769
201409 -0.767 100.428 -1.006
201412 -1.458 99.070 -1.939
201503 -1.800 99.621 -2.381
201506 -3.000 100.684 -3.926
201509 -1.800 100.392 -2.363
201512 -1.800 99.792 -2.377
201603 -2.400 100.470 -3.148
201606 -3.300 101.688 -4.276
201609 -3.600 101.861 -4.657
201612 -5.400 101.863 -6.986
201703 -4.800 102.862 -6.149
201706 -4.500 103.349 -5.738
201709 -4.200 104.136 -5.315
201712 -6.300 104.011 -7.982
201803 -6.300 105.290 -7.885
201806 -6.300 106.317 -7.809
201809 -7.800 106.507 -9.651
201812 -9.000 105.998 -11.189
201903 -12.900 107.251 -15.850
201906 0.900 108.070 1.097
201909 -9.600 108.329 -11.678
201912 -12.300 108.420 -14.950
202003 -12.900 108.902 -15.610
202006 -15.600 108.767 -18.900
202009 -12.900 109.815 -15.480
202012 -3.000 109.897 -3.597
202103 -4.200 111.754 -4.952
202106 -4.500 114.631 -5.173
202109 -0.600 115.734 -0.683
202112 -2.400 117.630 -2.689
202203 -2.260 121.301 -2.455
202206 -3.180 125.017 -3.352
202209 -2.110 125.227 -2.220
202212 -2.610 125.222 -2.747
202303 -4.240 127.348 -4.387
202306 -2.050 128.729 -2.099
202309 -2.270 129.860 -2.304
202312 -1.790 129.419 -1.823
202403 -0.830 131.776 -0.830

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corbus Pharmaceuticals Holdings  (LTS:0SZI) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Corbus Pharmaceuticals Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corbus Pharmaceuticals Holdings (LTS:0SZI) Business Description

Traded in Other Exchanges
Address
500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.

Corbus Pharmaceuticals Holdings (LTS:0SZI) Headlines

No Headlines